High-dose intravenous gammaglobulin for Kawasaki disease
…, M Kawarano, K Baba, T Kamiya, N Kiyosawa… - The Lancet, 1984 - Elsevier
The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery
lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus …
lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus …
Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)
…, S Ogawa, Y Nakamura, N Kiyosawa… - Pediatrics …, 2005 - Wiley Online Library
Abstract Diagnostic guidelines for Kawasaki Disease was revised to meet the present
situation in 2002. This issue intends to explain new guidelines and their backgrounds. Major …
situation in 2002. This issue intends to explain new guidelines and their backgrounds. Major …
Prevalence of coronary artery abnormality in incomplete Kawasaki disease
T Sonobe, N Kiyosawa, K Tsuchiya, S Aso… - Pediatrics …, 2007 - Wiley Online Library
Background: The aim of the present study was to determine the prevalence of coronary
artery abnormality (CAA) and other clinical features in patients with incomplete Kawasaki …
artery abnormality (CAA) and other clinical features in patients with incomplete Kawasaki …
A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats
For assessing carcinogenicity in animals, it is difficult and costly, an alternative strategy has
been desired. We explored the possibility of applying a toxicogenomics approach by using …
been desired. We explored the possibility of applying a toxicogenomics approach by using …
[HTML][HTML] Identification of circulating miRNAs differentially regulated by opioid treatment
K Toyama, N Kiyosawa, K Watanabe… - International journal of …, 2017 - mdpi.com
Emerging evidence demonstrates functional contributions of microRNAs (miRNAs) to μ-
opioid receptor (MOR) signaling, but the information so far has been mostly limited to their …
opioid receptor (MOR) signaling, but the information so far has been mostly limited to their …
Morphological and microarray analysis of T-2 toxin-induced rat fetal brain lesion
S Sehata, N Kiyosawa, T Makino, F Atsumi, K Ito… - Food and chemical …, 2004 - Elsevier
To examine morphological and gene expression changes induced by T-2 toxin in the fetal
brain in detail, pregnant rats on day 13 of gestation were treated orally with a single dose of …
brain in detail, pregnant rats on day 13 of gestation were treated orally with a single dose of …
Microarray analysis of T-2 toxin-induced liver, placenta and fetal liver lesions in pregnant rats
S Sehata, N Kiyosawa, F Atsumi, K Ito, T Yamoto… - Experimental and …, 2005 - Elsevier
Pregnant rats on day 13 of gestation were treated orally with 2mg/kg of T-2 toxin and
sacrificed at 1, 3, 6, 9 and 12h after the treatment (HAT). Histopathologically, the number of …
sacrificed at 1, 3, 6, 9 and 12h after the treatment (HAT). Histopathologically, the number of …
Toxicogenomic biomarkers for liver toxicity
N Kiyosawa, Y Ando, S Manabe… - Journal of toxicologic …, 2009 - jstage.jst.go.jp
Toxicogenomics (TGx) is a widely used technique in the preclinical stage of drug
development to investigate the molecular mechanisms of toxicity. A number of candidate …
development to investigate the molecular mechanisms of toxicity. A number of candidate …
Ethylene glycol monomethyl ether–induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family
…, W Saitoh, T Tanimoto, N Kiyosawa… - Toxicological …, 2010 - academic.oup.com
Ethylene glycol monomethyl ether (EGME) is a widely used industrial solvent known to
cause adverse effects to human and other mammals. Organs with high metabolism and …
cause adverse effects to human and other mammals. Organs with high metabolism and …
[HTML][HTML] Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
M Amitani, T Oba, N Kiyosawa, H Morikawa, T Chino… - BMC cancer, 2022 - Springer
Background The skeletal muscle index (SMI), which is calculated as the ratio of skeletal
muscle area at the third lumbar vertebral level divided by height squared, has been …
muscle area at the third lumbar vertebral level divided by height squared, has been …